Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 121,433 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Implantable Cardioverter-Defibrillators
Interventions: Not listed
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cluster Headache, Episodic
Interventions: Eptinezumab, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 24
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Multiple Myeloma
Interventions: LBH589, Lenalidomide; Drug · Combination Product
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 3
States / cities: San Francisco, California • Atlanta, Georgia • New York, New York

Conditions: Essential Hypertension
Interventions: Aliskiren, Placebo to Aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Zanesville, Ohio

Conditions: Tonsillitis
Interventions: Auricular acupuncture; Other
Lead sponsor: Defense and Veterans Center for Integrative Pain Management; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Fort Bragg, North Carolina

Conditions: Breast Cancer, Fatigue
Interventions: Combined Strength Training and Functional Endurance Exercise, Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 21 Years to 60 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neuroendocrine Carcinoma
Interventions: 68Ga-DOTATATE, PET/CT, 111In-pentetreotide OctreoScan, MRI; Drug · Diagnostic Test
Lead sponsor: Radio Isotope Therapy of America; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Childhood Apraxia of Speech
Interventions: Speech Motor Chaining without Biofeedback, Biofeedback, Distributed Practice, Massed --> Distributed Practice; Behavioral
Lead sponsor: Syracuse University; Other
Eligibility: 9 Years to 17 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Docetaxel-Carboplatin; Drug
Lead sponsor: Michael Mann; Network
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Primary Biliary Cirrhosis
Interventions: NGM282, Placebo; Biological
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 7
States / cities: Phoenix, Arizona • Coronado, California • Detroit, Michigan + 4 more

Conditions: Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions: Cetuximab:, Paclitaxel, Carboplatin; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Child Development, Premature Birth
Interventions: Training in Rating Emotional Connection; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 20 Years to 40 Years
Enrollment: 54 participants
Timeline: 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Volunteers on Chronic, Stable Antipsychotic Regimens
Interventions: A - 10 mg loxapine q 4 h x 3 (30 mg total), B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total), C - 5 mg loxapine q 4 h x 3 (15 mg total), D - inhaled placebo q 4 h x 3; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Health Behavior
Interventions: CBCT-informed training; Behavioral
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 7
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Lung Cancer
Interventions: paclitaxel, topotecan hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 18
States / cities: Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Bexagliflozin, Placebo for Bexagliflozin, Glimepiride, Placebo for Glimepiride; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 11
States / cities: Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 8 more

Conditions: Liver Disease
Interventions: naproxcinod; Drug
Lead sponsor: NicOx; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Opioid-induced Bowel Dysfunction
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 115
States / cities: Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 89 more

Conditions: Staphylococcus Aureus, Community-acquired Infections, Staphylococcal Skin Infections
Interventions: 2% chlorhexidine gluconate (CHG) impregnated cloths, Comfort Bath cloths (placebo cloths); Drug
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 35 Years
Enrollment: 1,563 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Quantico, Virginia

Conditions: Graft-versus-Host Disease
Interventions: Bortezomib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Treatment, Control
Interventions: Positive Behavior Support; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 5 Years to 12 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anxiety Depression
Interventions: Mindfulness-based art therapy, Art-only, Mindfulness-only; Other
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: VK2809, Placebos; Drug
Lead sponsor: Viking Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 68
States / cities: Madison, Alabama • Glendale, Arizona • Tucson, Arizona + 57 more

Conditions: Myopia
Interventions: comfilcon A, lotrafilcon B; Device
Lead sponsor: CooperVision, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 6
States / cities: Campbell, California • Whittier, California • Athens, Georgia + 3 more

Search by objective public record fields.

Deactivation of Implantable Cardioverter Defibrillator During Non-thoracic Surgical Procedures

Eptinezumab in Participants With Episodic Cluster Headache

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

Battlefield Auricular Acupuncture During Adult Tonsillectomies and Effect of Post op Pain and Nausea

Combined Strength Training and Functional Endurance Exercise Regimen on Cancer -Related Fatigue and Physical Performance

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Treating Childhood Apraxia of Speech

Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Students Education Training in Emotional Connection

Staccato Loxapine Multidose PK

CBCT for Spiritual Health Clinicians

Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects

Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates

Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease

Intervening With Children/Adolescents With FAS/ARND

Mindfulness-Based Art Therapy and Generation Z

A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH

A Multi-Center Study Comparing the Clinical Performance of Two Silicone Hydrogel Lenses Over 1 Month of Daily Wear